Xencor (XNCR) Stock Price, News & Analysis

Company Overview

Xencor, Inc. is a clinical-stage biopharmaceutical company that develops engineered antibodies and cytokine therapeutics for the treatment of cancer, autoimmune diseases and other serious medical conditions. The company’s platform is designed to modify antibody properties, including immune-system activation, half-life and biological activity, to create differentiated therapeutic candidates.

Xencor’s proprietary XmAb technology supports its internal research programs and collaborations with other biopharmaceutical companies. Its pipeline has included investigational medicines targeting immune and cancer-related pathways, including bispecific antibodies and cytokine-based therapies. The company has also licensed its antibody-engineering technology to external partners, contributing to the development of therapies based on XmAb designs.

Founded in 1997 and headquartered in Monrovia, California, Xencor serves global pharmaceutical and biotechnology markets through its research programs, licensing arrangements and strategic collaborations. The company’s leadership includes co-founder Bassil I. Dahiyat, who has served as president and chief executive officer and guides the company’s scientific and corporate development activities.

Key Stats

• Today's Range: $24.13 to $25.02
• 50-Day Range: $14.95 to $29.30
• 52-Week Range: $9.80 to $30.61
• Volume: 5.21 million shs
• Average Volume: 1.26 million shs
• Market Capitalization: $1.84 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.86
• Consensus Rating: Moderate Buy

Xencor Stock Analysis - MarketRank™

Xencor scored higher than 47% of companies evaluated by MarketBeat, and ranked 494th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Xencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Xencor has a consensus price target of $31.86, representing about 28.9% upside from its current price of $24.72.

Amount of Analyst Coverage

Xencor has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Xencor are expected to decrease in the coming year, from ($3.05) to ($3.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xencor is -11.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xencor is -11.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xencor has a P/B Ratio of 2.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

21.13% of the float of Xencor has been sold short.

Short Interest Ratio / Days to Cover

Xencor has a short interest ratio ("days to cover") of 9.53.

Change versus previous month

Short interest in Xencor has recently increased by 5.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xencor does not currently pay a dividend.

Dividend Growth

Xencor does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Xencor has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Healthcare companies.

Search Interest

Only 8 people have searched for XNCR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Xencor to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Xencor insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.08% of the stock of Xencor is held by insiders.

Percentage Held by Institutions

Xencor has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XNCR
• CIK: 1326732
• Web: www.xencor.com
• Phone: (626) 305-5900
• Fax: 626-305-0350
• Employees: 260
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Xencor: $31.86
• High Price Target: $46.00
• Low Price Target: $20.00
• Potential Upside/Downside: +28.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$91.92 million
• Net Margins: -155.59%
• Pretax Margin: -153.23%
• Return on Equity: -28.66%
• Return on Assets: -20.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.39

Sales & Book Value

• Annual Sales: $125.58 million
• Price / Sales: 14.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.90 per share
• Price / Book: 2.78

Miscellaneous

• Outstanding Shares: 74,350,000
• Free Float: 70,576,000
• Market Cap: $1.84 billion
• Optionable: Optionable
• Beta: 0.88